Stryker: Fair Value Says Hold as Premium Valuation Narrows 5% Margin
By stockpickr AI | April 16, 2026 | 10 min read
Investment Summary
Stryker (SYK) is a leader in the medical technology sector, currently appearing slightly overvalued based on recent DCF analysis compared to its current market price.
Investment Recommendation
Hold
Fair Value: $252.00
Current Price: $265.18
Upside/Downside: -4.97%
The DCF analysis yields an implied fair value slightly below the current market price of $265.18, suggesting limited immediate upside at current levels. While the company's fundamentals are excellent, the valuation requires a premium justified only by superior future execution.
Key Metrics
- Market Cap: $112.02B
- P/E Ratio: 34.7x
- Forward P/E: 25.9x
- Revenue Growth (YoY): 11.1%
- Net Margin: 16.5%
- ROE: 28.7%
- Debt/Equity: 0.38
- Dividend Yield: 0.75%
Strengths
- Strong operating margins: Reported Net Margin of 16.5% in the last full fiscal year, reflecting efficient cost management.
- Dominant position in Orthopedics: SYK holds a leading market share in hips and knees, a segment benefiting from favorable demographics.
- Consistent Free Cash Flow generation: FCF generation over the last five years has demonstrated reliable conversion from earnings.
- Low leverage: Debt-to-Equity ratio of 0.38 suggests a strong, conservative balance sheet capable of funding future growth.
Risk Factors
- High valuation multiples: Current P/E ratio of 34.7 suggests the stock is richly valued relative to historical averages and peers.
- Integration risk from large acquisitions: Continued success relies on effective integration of significant recent acquisitions.
- Regulatory and reimbursement changes: Potential slowdowns in procedures or adverse changes in pricing from healthcare payers pose a threat.